Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.

Date publication

août 2023

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESMOULINS Isabelle , Dr JOUANNAUD Christelle

Tous les auteurs :
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeulin T, Emile G, Gonçalves A, Ung M, Robert M, Jaffre A, Desmoulins I, Jouannaud C, Uwer L, Marc Ferrero J, Mouret-Reynier MA, Jacot W, Chevrot M, Delaloge S, Diéras V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37589218

Résumé

Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database.

Mots clés

HER2 positive, anti-HER2-targeted agents, breast cancer, de novo metastatic, pertuzumab, trastuzumab

Référence

Oncologist. 2023 08 17;: